HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maybelline Substantiates Anti-Aging Claims In NAD Case

This article was originally published in The Rose Sheet

Executive Summary

Maybelline New York demonstrated that claims its Instant Age Rewind Eraser Treatment Makeup foundation could “erase” signs of aging merely play on the product name and are not taken literally by consumers, according to the National Advertising Division.

You may also be interested in...



L’Oreal Appeals NAD Ruling On Eyelash Enhancement

A National Advertising Division decision concerning implied and express claims in L’Oreal USA ads for mascara products reinforces the watchdog’s position on artificial enhancements to cosmetic advertising that exaggerate potential product benefits – this time focusing on physical (versus digital) alterations.

J&J Employs L’Oreal-Did-It-So-Why-Can’t-We Defense In NAD Case

The National Advertising Division recommends that Johnson & Johnson discontinue and modify claims for its Neutrogena Rapid Wrinkle Repair Moisturizer (Night), rejecting a consumer perception study that J&J claims is modeled after a L’Oreal study the watchdog group praised in a November 2010 case.

NAD’s Patience For Photoshopping In Beauty Ads May Be Wearing Thin

The National Advertising Division was “troubled” that a model’s lashes were digitally enhanced in a Procter & Gamble ad for CoverGirl NatureLuxe Mousse Mascara. NAD’s position on the firm’s post-production tinkering is consistent with recent decisions from its U.K. counterpart, the Advertising Standards Authority

Related Content

UsernamePublicRestriction

Register

RS017347

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel